Colorectal Cancer: Update Bulletin #2 [March 2018]

February 2018 | - | ID: C0FB0F134CCEN
FirstWord

Abstracts

Gain new key opinion leader (KOL) insights on the latest events happening in the CRC treatment landscape

Topics covered include expert opinions on; the potential of MabVax Therapeutics’ human antibody-based radioimmunotherapy product, MVT-1075; views on the new clinical data presented at the ASCO 2018 Gastrointestinal Cancers Symposium for Taiho Oncology’s Lonsurf (trifluridine and tipiracil); views on new data announced from the Phase II CheckMate-142 trial evaluating Opdivo (nivolumab; Merck & Co.) and Yervoy (ipilimumab; BMS) for the treatment of patients with DNA mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) mCRC.

Business Questions:

• How do KOLs perceive MVT-1075’s mechanism of action?
• What are the experts’ views on targeting CA19-9 positive malignancies?
• What concerns, if any, do KOLs have regarding MVT-1075?
• How do KOLs view the NLR marker’s potential role in guiding clinical decisions related to Lonsurf?
• What are the KOLs’ views on the Lonsurf safety and tolerability data in elderly patients?
• How do KOLs perceive the potential of Lonsurf and oxaliplatin in combination?
• What are the KOLs’ views on the new data presented from the CheckMate-142 trial?
• Where in the treatment paradigm do KOLs believe the nivolumab plus ipilimumab combination should be used?
• What concerns do KOLs raise about using nivolumab and ipilimumab in combination?